Role of p53 and Rb in ovarian cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-0-387-68969-2_9PMID 18546622PMCID PMC2774127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

  2007influential reference
• Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System

  2006cited by this paper
• A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

  2006influential reference
• Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties

  2006cited by this paper
• Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.

  2006influential reference
• P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.

  2006cited by this paper
• Characterization of stem cell-like cancer cells in immune-competent mice.

  2006cited by this paper
• Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

  2006cited by this paper
• Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters

  2005cited by this paper
• Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation

  2005influential reference
• p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53

  2005cited by this paper
• Somatic misexpression of germline P granules and enhanced RNA interference in retinoblastoma pathway mutants

  2005cited by this paper
• Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.

  2005cited by this paper
• Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2.

  2005cited by this paper
• Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications

  2005cited by this paper
• Loss of TNF-α-regulated COX-2 expression in ovarian cancer cells

  2005cited by this paper
• Does hormone replacement therapy prevent epithelial ovarian cancer?

  2005cited by this paper
• An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas: Significantly Higher Expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in High-Grade Neoplasms

  2005influential reference
• Use of multiphoton imaging for studying cell migration in the mouse.

  2005cited by this paper
• p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.

  2005influential reference
• Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

  2005cited by this paper
• Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells.

  2005cited by this paper
• The role of p53 in hypoxia-induced apoptosis.

  2005cited by this paper
• Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer

  2004influential reference
• A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

  2004cited by this paper
• Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.

  2004influential reference
• Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients

  2004cited by this paper
• Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages

  2004cited by this paper
• Pathology of Ovarian Neoplasms in Genetically Modified Mice.

  2004influential reference
• Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

  2003cited by this paper
• Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• K-RAS Mutations in Ovarian and Extraovarian Lesions of Serous Tumors of Borderline Malignancy

  2003cited by this paper
• Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

  2003influential reference
• Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients.

  2003cited by this paper
• Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2003cited by this paper
• Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation

  2003cited by this paper
• Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins

  2003influential reference
• Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor)

  2003cited by this paper
• Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

  2003influential reference
• Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

  2003influential reference
• The RB and p53 pathways in cancer.

  2002influential reference
• Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

  2002cited by this paper
• Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling.

  2002cited by this paper
• Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53*

  2002cited by this paper
• Diverse tumorigenic pathways in ovarian serous carcinoma.

  2002cited by this paper
• Modelling the molecular circuitry of cancer

  2002cited by this paper
• Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation

  2002cited by this paper
• Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.

  2002cited by this paper
• Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

  2002cited by this paper
• In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy

  2001influential reference
• Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210

  2001cited by this paper
• p53 mutation is infrequent in clear cell carcinoma of the ovary.

  2001cited by this paper
• Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy

  2001influential reference
• Combined analysis of p53 and RB pathways in epithelial ovarian cancer.

  2001influential reference
• Ovarian surface epithelium: biology, endocrinology, and pathology.

  2001influential reference
• Menstrual and reproductive factors in relation to ovarian cancer risk

  2001cited by this paper
• Loss of Heterozygosity at the RB-1 Locus and pRB Immunostaining in Epithelial Ovarian Tumors: A Molecular, Immunohistochemical, and Clinicopathologic Study

  2001influential reference
• Multiphoton microscopy in biological research.

  2001cited by this paper
• Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.

  2001cited by this paper
• The Gene Encoding p202, an Interferon-inducible Negative Regulator of the p53 Tumor Suppressor, Is a Target of p53-mediated Transcriptional Repression*

  2001cited by this paper
• Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.

  2001cited by this paper
• Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

  2001influential reference
• Possible associations among expression of p14ARF, p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas

  2001cited by this paper
• Experience-dependent plasticity of dendritic spines in the developing rat barrel cortex in vivo

  2000cited by this paper
• Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

  2000cited by this paper
• Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.

  2000cited by this paper
• Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

  2000cited by this paper
• Leukocytes in ovarian function.

  2000cited by this paper
• p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect

  2000cited by this paper
• Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.

  2000influential reference
• In search of the tumour-suppressor functions of BRCA1 and BRCA2

  2000influential reference
• Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.

  2000cited by this paper
• Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

  2000cited by this paper
• Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.

  1999influential reference
• Methylation of p16INK4A in primary gynecologic malignancy.

  1999cited by this paper
• Possible role of ovarian epithelial inflammation in ovarian cancer.

  1999cited by this paper
• CA 125: fundamental and clinical aspects.

  1999cited by this paper
• Differences inp16Gene Methylation and Expression in Benign and Malignant Ovarian Tumors

  1999cited by this paper
• Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.

  1999influential reference
• The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer.

  1999influential reference
• CDKN2A gene inactivation in epithelial sporadic ovarian cancer

  1999cited by this paper
• Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer

  1999cited by this paper
• Retinoblastoma protein represses transcription by recruiting a histone deacetylase

  1998cited by this paper
• No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.

  1998cited by this paper
• Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.

  1998cited by this paper
• Rb interacts with histone deacetylase to repress transcription.

  1998cited by this paper
• Expression of Prostaglandin G/H Synthase Type 1, but not Type 2, in Human Ovarian Adenocarcinomas

  1998cited by this paper
• p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper‐methylation or mutation in endometrioid and mucinous tumors

  1998influential reference
• Retinoblastoma protein recruits histone deacetylase to repress transcription

  1998cited by this paper
• In vitro analysis of the dominant negative effect of p53 mutants.

  1998cited by this paper
• Retinoblastoma protein expression in ovarian epithelial neoplasms.

  1998cited by this paper
• Alteration of p16 and p15 genes in common epithelial ovarian tumors

  1997influential reference
• TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

  1997cited by this paper
• p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma

  1997cited by this paper
• K‐ras mutations in mucinous ovarian tumors

  1997cited by this paper

• Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers

  2025cites this paper
• Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer

  2024cites this paper
• Advances in understanding the molecular mechanisms of borderline ovarian tumors

  2024cites this paper
• Bioinformatics analysis proposes a possible role for long noncoding RNA MIR17HG in retinoblastoma

  2024cites this paper
• The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer

  2023cites this paper
• Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers

  2023cites this paper
• Epigenetic Status of FBXW7 Gene and Its Role in Ovarian Cancer Pathogenesis

  2023cites this paper
• Triple Reporter Assay: A Non-Overlapping Luciferase Assay for the Measurement of Complex Macromolecular Regulation in Cancer Cells Using a New Mushroom Luciferase–Luciferin Pair

  2023cites this paper
• The regulatory landscape of retinoblastoma: a pathway analysis perspective

  2022cites this paper
• The Senescence-Associated Secretory Phenotype in Ovarian Cancer Dissemination.

  2022cites this paper
• Integrative analysis of the expression and prognosis for CENPs in ovarian cancer.

  2022cites this paper
• Ovarian Microbiota, Ovarian Cancer and the Underestimated Role of HPV

  2022cites this paper
• The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance - A focus on signaling pathways interplay.

  2022cites this paper
• PROGNOSTIC CLINICAL, MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL MARKERS OF LOW-GRADE SEROUS OVARIAN CARCINOMAS OF WOMEN WITH SEROUS BORDERLINE TUMORS IN ANAMNESIS

  2022cites this paper
• MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer

  2021cites this paper
• Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer

  2021cites this paper
• DNA damage response and PD-1/PD-L1 pathway in ovarian cancer.

  2021cites this paper
• Computational and Artificial Intelligence Techniques for Drug Discovery and Administration

  2021cites this paper
• P53 Plays an Important Role in the Early Stage of Autologous Heterotopic Transplantation of Ovaries into the Backs of Mice.

  2020cites this paper
• Clinical significance of β-catenin, hTERT, p53, and Wnt7A as biomarkers for ovarian cancer

  2020cites this paper
• The hallmarks of ovarian cancer: proliferation and cell growth

  2020cites this paper
• Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach

  2020cites this paper
• IMMUNOCYTOCHEMICAL ANALYSIS OF ASPIRATION MATERIAL FROM THE UTERINE SEROUS OVARIAN CANCER DETECTION

  2020cites this paper
• Exploring Dysregulated Signaling Pathways in Cancer.

  2020cites this paper
• Charactor of JNK and P53 in Taxol-Induced Apoptotic Signaling in SKOV3 Human Ovarian Cancer Cell Proliferation

  2019cites this paper
• Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer

  2019cites this paper
• Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer

  2019cites this paper
• Deep Pathway Analysis V2.0: A Pathway Analysis Framework Incorporating Multi-Dimensional Omics Data

  2019cites this paper
• Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary

  2019cites this paper
• Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer

  2018cites this paper
• CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer

  2018cites this paper
• Evaluation of the mevalonate pathway as a target for the treatment of ovarian cancer

  2018cites this paper
• Investigation of the anti-cancer properties of natural products and synthetic analogues with NQO2 inhibiting potential

  2018cites this paper
• Increased rounds of gonadotropin stimulation have side effects on mouse fallopian tubes and oocytes.

  2018cites this paper
• A computational framework for complex disease stratification from multiple large-scale datasets

  2018cites this paper
• miRNAs and ovarian cancer: An overview

  2018cites this paper
• Molecularly targeted therapies for p53-mutant cancers

  2017cites this paper
• KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice

  2017cites this paper
• An Extension of Deep Pathway Analysis: A Pathway Route Analysis Framework Incorporating Multi-dimensional Cancer Genomics Data

  2017cites this paper
• The Role of Opportunistic Bilateral Salpingectomy vs Tubal Occlusion or Ligation for Ovarian Cancer Prophylaxis.

  2017cites this paper
• Haemoglobin in pelvic fluid rescues Fallopian tube epithelial cells from reactive oxygen species stress and apoptosis

  2016cites this paper
• Roles of JNK and P53 in Taxol-Induced Apoptotic Signaling in SKOV3 Human Ovarian Cancer Cells

  2016cites this paper
• Categorization of ovarian tumors , with emphasis on fallopian tubal changes in serous tumors , using p 53 as an IHC marker ‖ is a bonafide work done

  2016cites this paper
• Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53

  2016cites this paper
• An overview of long non-coding RNAs in ovarian cancers

  2016cites this paper
• [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].

  2015cites this paper
• Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

  2015cites this paper
• Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells

  2015cites this paper
• RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

  2014cites this paper
• Molecular Study of P53- and Rb-Tumor Suppressor Genes in Human Papilloma Virus-Infected Breast Cancers

  2014cites this paper
• Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.

  2013cites this paper
• Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

  2012cites this paper
• Modern Trends into the Epidemiology and Screening of Ovarian Cancer. Genetic Substrate of the Sporadic Form

  2012cites this paper
• Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

  2012cites this paper
• Protein expression changes in ovarian cancer during the transition from benign to malignant.

  2012cites this paper
• The Role Of P53/Mir34/Met Pathway In Epithelial Ovarian Cancer Pathogenesis

  2012influential citation
• In search of new prognostic molecular markers in ovarian cancer

  2012cites this paper
• Role of E-cadherin in the serous borderline ovarian tumor and low-grade serous ovarian carcinoma cell invasion

  2012influential citation
• Immunity and immune suppression in human ovarian cancer.

  2011cites this paper
• Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.

  2011cites this paper
• Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

  2011cites this paper
• Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization

  2011cites this paper
• Claudin and p53 expression in vulvar lichen sclerosus and squamous-cell carcinoma

  2011cites this paper
• Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.

  2011influential citation
• MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF

  2011cites this paper
• Functional Polymorphisms of the hOGG1 Gene Confer Risk to Type 2 Epithelial Ovarian Cancer in Chinese

  2011cites this paper
• Frequent Downregulation of miR-34 Family in Human Ovarian Cancers

  2010cites this paper
• MicroRNA and ovarian cancer.

  2008cites this paper